Edwards Lifesciences Accrued litigation decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $87.50M to $0.00. Over 4 years (FY 2020 to FY 2025), Accrued litigation shows an upward trend with a 7.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase signals heightened legal risk or unfavorable developments in ongoing litigation, while a decrease suggests resolution of claims.
This represents the estimated financial liability for pending legal claims or regulatory disputes that are considered pr...
Varies significantly based on the legal environment and operational footprint of the company.
non_current_liabilities_litigation_reserve_current| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.00M | $54.40M | $51.30M | $53.30M | $95.40M | $69.20M | $65.90M | $69.10M | $76.10M | $76.70M | $75.10M | $73.80M | $87.50M | $77.30M | $64.80M | $50.00M | $0.00 |
| QoQ Change | — | +8.8% | -5.7% | +3.9% | +79.0% | -27.5% | -4.8% | +4.9% | +10.1% | +0.8% | -2.1% | -1.7% | +18.6% | -11.7% | -16.2% | -22.8% | -100.0% |
| YoY Change | — | — | — | — | +90.8% | +27.2% | +28.5% | +29.6% | -20.2% | +10.8% | +14.0% | +6.8% | +15.0% | +0.8% | -13.7% | -32.2% | -100.0% |